Sierrah Ellenbecker Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Prentice St, Granite Falls, MN 56241 Phone: 320-564-2339 |
Christopher Martinson Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Prentice St, Granite Falls, MN 56241 Phone: 320-564-2339 |
Janel Torgerson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 345 10th Ave, Granite Falls, MN 56241 Phone: 320-564-6219 Fax: 320-313-3311 |
James Fromm Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Prentice St, Granite Falls, MN 56241 Phone: 320-564-2339 |
John Eugene Linden, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Prentice St, Granite Falls, MN 56241 Phone: 320-564-2339 Fax: 320-564-5790 |
News Archive
Blood pressure medication can prevent heart attacks and strokes - even in people with normal blood pressure. That's the finding of late breaking research presented in a Hot Line session today at ESC Congress 2020.
Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
BioCenter at Southwestern Medical District offers a springboard to drive biomedical innovation in North Texas to business operations, from earliest stage startups exploring bold new ideas to established companies needing an entire custom-designed floor to bring products to fruition.
Supelco, a division of Sigma-Aldrich®, announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core™ particle design. This column design exhibits very high column efficiency, providing a stable, reversed phase packing with a pore structure and pore size that is optimized for reversed-phase HPLC separations of peptides and polypeptides.
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has been featured in an in-depth report by Griffin Securities, a New York-based brokerage firm, highlighting the importance of the role that cancer stem cell (CSCs) targeting technology such as that employed by its lead product candidate, ICT-121, may play in developing future cancer treatments.
› Verified 4 days ago